• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    4/12/23 1:31:18 PM ET
    $AGLE
    $BACK
    $BBLN
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $AGLE alert in real time by email

    Gainers

    • Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 105.5% to $0.99 during Wednesday's regular session. As of 13:30 EST, this security is trading at a volume of 75.9 million shares, making up 2955.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.9 million.
    • Bullfrog AI Hldgs (NASDAQ:BFRG) shares rose 31.32% to $5.66. The current volume of 5.0 million shares is 288.0% of Bullfrog AI Hldgs's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $31.9 million.
    • X4 Pharmaceuticals (NASDAQ:XFOR) stock rose 28.77% to $1.22. The current volume of 9.1 million shares is 996.3% of X4 Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $149.5 million.
    • Hillstream BioPharma (NASDAQ:HILS) stock rose 28.12% to $1.08. As of 13:30 EST, Hillstream BioPharma's stock is trading at a volume of 4.1 million, which is 131.0% of its average full-day volume over the last 100 days. The company's market cap stands at $12.4 million.
    • Babylon Holdings (NYSE:BBLN) stock moved upwards by 22.22% to $7.48. The current volume of 141.5K shares is 285.2% of Babylon Holdings's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $185.9 million.
    • GlucoTrack (NASDAQ:GCTK) shares increased by 21.89% to $2.39. As of 13:30 EST, GlucoTrack's stock is trading at a volume of 19.2 million, which is 965.6% of its average full-day volume over the last 100 days. The company's market cap stands at $37.0 million.

    Losers

    • Cutera (NASDAQ:CUTR) shares declined by 26.3% to $19.96 during Wednesday's regular session. Trading volume for Cutera's stock is 3.8 million as of 13:30 EST. This is 674.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $394.9 million.
    • Lixte Biotech Hldgs (NASDAQ:LIXT) shares decreased by 21.26% to $0.67. As of 13:30 EST, Lixte Biotech Hldgs's stock is trading at a volume of 371.8K, which is 27.8% of its average full-day volume over the last 100 days. The company's market cap stands at $11.1 million.
    • Aeglea BioTherapeutics (NASDAQ:AGLE) stock decreased by 21.17% to $0.2. Trading volume for this security as of 13:30 EST is 5.8 million, which is 2184.1% of its average full-day volume over the last 100 days. The company's market cap stands at $13.2 million.
    • PLx Pharma (NASDAQ:PLXP) shares declined by 17.43% to $0.1. As of 13:30 EST, this security is trading at a volume of 28.4 million shares, making up 780.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.8 million.
    • Ontrak (NASDAQ:OTRKP) stock declined by 16.98% to $0.51.
    • IMAC Hldgs (NASDAQ:BACK) shares fell 15.11% to $0.16. Trading volume for IMAC Hldgs's stock is 5.9 million as of 13:30 EST. This is 353.1% of its average full-day volume over the last 100 days. The company's market cap stands at $5.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGLE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGLE
    $BACK
    $BBLN
    $BFRG

    CompanyDatePrice TargetRatingAnalyst
    X4 Pharmaceuticals Inc.
    $XFOR
    3/9/2026$12.00Buy
    Guggenheim
    X4 Pharmaceuticals Inc.
    $XFOR
    12/5/2025$10.00Buy
    Stifel
    Cutera Inc.
    $CUTR
    3/22/2024Underperform → Mkt Perform
    William Blair
    X4 Pharmaceuticals Inc.
    $XFOR
    12/12/2023$3.00 → $1.00Buy → Neutral
    B. Riley Securities
    X4 Pharmaceuticals Inc.
    $XFOR
    8/30/2023$3.00Buy
    B. Riley Securities
    Cutera Inc.
    $CUTR
    7/27/2023$14.00 → $18.00Underweight → Neutral
    Piper Sandler
    Cutera Inc.
    $CUTR
    5/11/2023Outperform → Mkt Perform
    William Blair
    Cutera Inc.
    $CUTR
    5/10/2023$14.00Underweight
    Piper Sandler
    More analyst ratings

    $AGLE
    $BACK
    $BBLN
    $BFRG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones

    RUTHERFORD, N.J., March 27, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today provided a comprehensive recap of the critical operational milestones which have positioned the Company to submit an IDE to the U.S. Food and Drug Administration (FDA) for its novel continuous blood glucose monitoring (CBGM) technology, with a goal to file requisite documents with the FDA during Q2 of 2026. "In 2025 we made meaningful progress in advancing the development of our fully implantable continuous blood glucose monitoring tec

    3/27/26 8:01:00 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    BullFrog AI Unveils bfARENAS™ Scenario-based Decision Engine

    GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, today unveiled bfARENAS™, a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design, bolstering its end-to-end AI intelligence workflow. The Company will host a webinar in partnership with Xtalks Life Sciences on bfARENAS™ on March 27, 2026 at 11 a.m. ET. Organizations across biotech, pharma, and clinical research operate in high-uncertainty environments where timelines are lon

    3/25/26 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    - Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for the Treatment of WHIM Syndrome in the European Union - - Balance Sheet Provides Cash Runway through 2028 - BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update. "Our focus remains on our pivotal 4WARD trial in chronic neutropenia as we execute our strategy to deliver

    3/17/26 7:15:00 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGLE
    $BACK
    $BBLN
    $BFRG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XOLREMDI issued to X4 PHARMACEUTICALS INC

    Submission status for X4 PHARMACEUTICALS INC's drug XOLREMDI (ORIG-1) with active ingredient MAVORIXAFOR has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218709, Application Classification: Type 1 - New Molecular Entity

    4/29/24 2:36:51 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGLE
    $BACK
    $BBLN
    $BFRG
    SEC Filings

    View All

    GlucoTrack Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Glucotrack, Inc. (0001506983) (Filer)

    3/27/26 8:25:24 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Creative Medical Technology Holdings Inc.

    10-K - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)

    3/20/26 4:45:28 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    3/20/26 4:05:18 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $BACK
    $BBLN
    $BFRG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on X4 Pharmaceuticals with a new price target

    Guggenheim initiated coverage of X4 Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    3/9/26 9:13:19 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stifel resumed coverage on X4 Pharmaceuticals with a new price target

    Stifel resumed coverage of X4 Pharmaceuticals with a rating of Buy and set a new price target of $10.00

    12/5/25 8:46:35 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cutera upgraded by William Blair

    William Blair upgraded Cutera from Underperform to Mkt Perform

    3/22/24 7:28:54 AM ET
    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AGLE
    $BACK
    $BBLN
    $BFRG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Craig Adam R bought $249,997 worth of shares (86,206 units at $2.90), increasing direct ownership by 30% to 376,087 units (SEC Form 4)

    4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

    10/27/25 6:40:40 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Commercial Officer Baldry Mark bought $2,561 worth of shares (1,032 units at $2.48), increasing direct ownership by 4% to 25,337 units (SEC Form 4)

    4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

    5/20/25 4:51:03 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Ruiz Jorge bought $3 worth of shares (1 units at $2.69), increasing direct ownership by 0.00% to 141,230 units (SEC Form 4)

    4 - IMAC Holdings, Inc. (0001729944) (Issuer)

    3/18/25 12:01:15 PM ET
    $BACK
    Medical Specialities
    Health Care

    $AGLE
    $BACK
    $BBLN
    $BFRG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Bridger Gary

    4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

    1/7/26 4:00:12 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director De Craecker Francoise

    4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

    1/5/26 4:06:13 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Wyzga Michael S

    4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

    1/5/26 4:05:30 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGLE
    $BACK
    $BBLN
    $BFRG
    Leadership Updates

    Live Leadership Updates

    View All

    LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary ("Liora"). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc. Over his

    2/18/26 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

    Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD, MBA Strengthened balance sheet, cash and cash equivalents expected to fund operations through March 2026, including long-term feasibility clinical trials and achievement of related milestones Rutherford, NJ, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results

    11/13/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team

    RUTHERFORD, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Usman Latif, MD, MBA, has been named to Glucotrack's clinical advisory team, providing strategic counsel as the Company advances its epidural glucose monitoring applications alongside its continuous blood glucose monitor (CBGM). "Dr. Latif is a prominent pain management specialist and opinion leader with deep expertise in neuromodulation and treatment of Painful Diabetic Neuropathy (PDN). His exceptional knowledge in pain man

    10/29/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $AGLE
    $BACK
    $BBLN
    $BFRG
    Financials

    Live finance-specific insights

    View All

    LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

    Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT) a biotech company focused on advancing cancer treatments, today announced it has completed the acquisition of Liora Technologies Europe Ltd., a UK-based company pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora will become a wholly owned subsidiary of LIXTE. The acquisition includes Liora's proprietary flagship technology LiGHT Sys

    11/25/25 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

    4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial XOLREMDI® net U.S. revenues $3.5 million since May 2024 launch Conference call and webcast today at 8:30 am ET BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2025, and highlighted key recent events and expected upcoming milestones. "The first quarter of 2025 was an

    5/1/25 6:01:00 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

    BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the first quarter ended March 31, 2025 and provide corporate updates on Thursday, May 1, 2025. The company will host a conference call and webcast on the same day at 8:30 a.m. EDT. The conference call can be accessed by dialing 1-800-343-4849 from the United States or 1-203-518-9848 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals' website at www.x4pharma.com. Foll

    4/24/25 8:03:00 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGLE
    $BACK
    $BBLN
    $BFRG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc.

    SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

    11/12/24 5:59:35 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cutera Inc.

    SC 13G/A - CUTERA INC (0001162461) (Subject)

    11/12/24 2:37:12 PM ET
    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc.

    SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

    11/4/24 2:15:54 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care